Skip to content
Open Imaging Index
MRI PET Brain

IMAP+ (Caen)

IMAP+: Imagerie Multimodale de la maladie d'Alzheimer à un stade Précoce (multimodal neuroimaging of early Alzheimer's disease), Caen

Brain MRI, FDG and amyloid PET, biomarkers and cognition of healthy adults and people with subjective decline, MCI or Alzheimer's disease, collected to find early markers of the disease and follow their change. 242 people from one centre in Caen, France. Shared on request.

Go to dataset Edit Report

Overview

IMAP+ is a research cohort run at the Cyceron imaging centre in Caen, France, sponsored by Caen University Hospital with Inserm. It follows healthy adults and people at different stages of the Alzheimer's clinical continuum with cognitive testing, blood and CSF biomarkers, APOE genotyping, structural and functional MRI, FDG-PET and florbetapir amyloid PET, to find early markers of the disease and track how they change. It is registered as NCT01638949, started in May 2012 and was completed in 2022. It continues the earlier IMAP protocol (NCT01554202, started January 2008), and the group's papers refer to the shared data as IMAP data.

Composition

The registry reports 242 enrolled participants in eight arms: young (18 to 40), middle-aged (40 to 60) and older (over 60) healthy controls, people with subjective cognitive impairment, amnestic MCI, probable Alzheimer's disease (MMSE of at least 15), asymptomatic relatives from families with autosomal dominant mutations, and non-degenerative amnesic syndromes. Participants are French-speaking and right-handed. Arm sizes are not reported. Published analyses use subsets; Moulinet et al. (2022), for example, studied 56 older controls, 35 people with subjective decline, 28 with MCI and 28 with Alzheimer's dementia.

Acquisition

All imaging is done on one MRI and one PET scanner at Cyceron. MRI uses a Philips Achieva 3 T with 3D T1-weighted fast field echo (1 mm slices), 2D T2-weighted spin echo and 3D FLAIR; the registry also lists resting-state and task fMRI. PET uses a GE Discovery RX VCT 64 PET-CT with FDG and florbetapir, each acquired from 50 minutes after injection. The protocol plans repeat imaging after 18 months and, for some groups, 36 months.

Known limitations

  • Not public. Requests go to the sponsor and the principal investigator; no terms are published.
  • No source found gives cohort-wide counts by group, sex, age or modality. Modality and scanner rows come from analysis subsets and are lower bounds.
  • The number of participants from the earlier IMAP protocol, and its overlap with IMAP+, is not reported.

Cohort

Aggregate numbers from the sources below. Bars are relative to the 242 subjects.

Contrast / sequence

Groups can overlap

  • T1-weighted 142 59%
  • T2-weighted 142 59%
  • FLAIR 142 59%

Methods in Garnier-Crussard et al. 2025, Scientific Reports (PMC12583515)

Scanner vendor

  • Philips 142 59%
  • GE HealthCare 142 59%

Methods in Garnier-Crussard et al. 2025, Scientific Reports (PMC12583515)

Field strength

  • 3 T 142 59%

Methods in Garnier-Crussard et al. 2025, Scientific Reports (PMC12583515)

PET tracer

  • [18F]FDG 147 61%
  • [18F]florbetapir 147 61%

Materials and Methods, Neuroimaging Data and Processing in Moulinet et al. 2022, Frontiers in Aging Neuroscience

Condition

Groups can overlap

  • Healthy control 56 23%
  • Subjective cognitive decline 35 14%
  • Mild cognitive impairment 28 12%
  • Alzheimer's disease 28 12%

Table 1, Materials and Methods, Participants in Moulinet et al. 2022, Frontiers in Aging Neuroscience

Country

  • France 242 100%

Contacts and Locations in ClinicalTrials.gov NCT01638949, IMAP+ study record

License and access

Our reading of the license, not legal advice. Before you use the data, read the original license and confirm that your use is allowed. We take no responsibility for how you use a dataset. Full disclaimer

Access
On request

Ask the authors or the data holder. No published process or terms, and access is at their discretion

Access page

No published license or data use terms

The data holder has published no license and no data use terms. Any use, sharing or commercial right has to be agreed with the data holder, and nothing can be assumed to be allowed. Default copyright and data protection law still apply.

Moulinet et al. (2022) state that "IMAP data are made available upon request to the sponsor (Caen University Hospital) and the principal investigator". Garnier-Crussard et al. (2025) state that data are available on reasonable request "pending approval by the study coordinator". No agreement or terms are published.

Original license text Checked 2026-10-08

What you can do

  • Commercial use Not stated
  • Not stated
  • Train ML models Not stated
  • Create derived data Not stated
  • Publish results Not stated

What you can share

  • Share the data Not stated
  • Share derived data Not stated
  • Share trained models Not stated

What you must do

  • Cite or credit Not stated
  • Share alike Not stated
  • Sign an agreement Not stated
  • Ethics approval Not stated
  • Manuscript review Not stated
  • Release code Not stated
  • Return results Not stated
  • Delete after use Not stated

Limits

  • No re-identification Not stated
  • Location limits Not stated

Citation

Moulinet I, Touron E, Mézenge F, Dautricourt S, De La Sayette V, Vivien D, Marchant NL, Poisnel G, Chételat G. Depressive symptoms have distinct relationships with neuroimaging biomarkers across the Alzheimer's clinical continuum. Frontiers in Aging Neuroscience 14, 899158 (2022). doi:10.3389/fnagi.2022.899158

Sources

Every number on this page comes from one of these documents. Each chart names the table or page it is taken from. The raw numbers are in stats.csv.